Valneva SE (VALN)

Revenue by Segment

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Development and Commercialization of Prophylactic Vaccines	174.66M	169.58M	153.71M	361.30M	348.09M
Development and Commercialization of Prophylactic Vaccines Growth	3.00%	10.32%	-57.46%	3.80%	-
Total	174.66M	169.58M	153.71M	361.30M	348.09M
Total Growth	3.00%	10.32%	-57.46%	3.80%	215.52%

Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
United States	53.61M	48.59M	32.96M	-23.80M	40.34M
United States Growth	10.32%	47.41%	-	-	10.78%
Canada	30.13M	32.32M	28.19M	18.90M	4.23M
Canada Growth	-6.79%	14.64%	49.14%	347.33%	-52.86%
Germany	17.47M	18.37M	13.50M	68.53M	726.00K
Germany Growth	-4.93%	36.07%	-80.30%	9339.26%	-89.72%
France	14.67M	7.22M	5.87M	46.61M	1.00M
France Growth	103.16%	23.08%	-87.41%	4560.80%	36.24%
Nordics	13.90M	13.94M	12.70M	12.04M	2.44M
Nordics Growth	-0.28%	9.78%	5.41%	394.38%	-15.00%
Other Europe	13.88M	9.06M	9.34M	18.74M	2.08M
Other Europe Growth	53.24%	-2.99%	-50.19%	803.13%	55.55%
United Kingdom	12.64M	19.49M	20.27M	181.13M	2.71M
United Kingdom Growth	-35.12%	-3.83%	-88.81%	6591.13%	46.56%
Austria	9.47M	15.90M	14.58M	21.79M	9.34M
Austria Growth	-40.41%	9.01%	-33.08%	133.30%	180.26%
Rest Of World	8.90M	4.69M	16.31M	17.36M	134.00K
Rest Of World Growth	89.66%	-71.23%	-6.06%	12855.22%	-96.04%
Total	174.66M	169.58M	153.71M	361.30M	62.98M
Total Growth	3.00%	10.32%	-57.46%	473.64%	-4.48%

Source: S&P Global Market Intelligence.